Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AB102 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SAD Part | EXPERIMENTAL | Escalating single oral doses of AB102 will be given to participants |
| SAD Part Placebo | EXPERIMENTAL | Escalating single oral doses of placebo will be given to participants |
| MAD Part | PLACEBO_COMPARATOR | Escalating multiple oral doses of AB102 will be given to participants |
| MAD Part Placebo | PLACEBO_COMPARATOR | Escalating multiple oral doses of placebo will be given to participants |
| Name | Type | Description |
|---|---|---|
| AB102 | DRUG | Administered orally as specified in the treatment arm |
| Placebo | OTHER | Administered orally as specified in the treatment arm |
Inclusion Criteria: * Understands the study procedures in the Informed Consent Form and is willing and able to comply with the protocol. * BMI: 19.0 to 30.0 kg/m2, inclusive, at screening. * All prescribed medication must have been stopped at least 30 days prior to admission to the clinical site. A...
AB102 is an investigational small molecule developed by Arcus Biosciences, Inc. It is being studied in a Phase 1 clinical trial in healthy volunteers. AB102 is designed to act on MRGPRX2, a receptor target. The program is in early clinical development and has not been approved for any use.
AB102 targets MRGPRX2, a receptor. MRGPRX2 is the molecular target of this small molecule. By binding this receptor, AB102 is designed to modulate MRGPRX2-mediated signaling. The target class is a receptor, and the compound is being evaluated in a Phase 1 study in healthy participants.
AB102 is being developed by Arcus Biosciences, Inc., which trades on the Nasdaq under the ticker RCUS. Arcus Biosciences is the sponsor of the Phase 1 clinical trial evaluating AB102. The company is a clinical-stage biopharmaceutical company, and AB102 is one of its investigational small molecule programs.
AB102 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA or any other regulatory agency. The Phase 1 program consists of one recruiting trial with a planned enrollment of 130 participants. No Phase 1 trials of AB102 have been completed to date.
AB102 is being evaluated in one clinical trial, NCT07662057, titled A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants. The trial is a Phase 1, randomized, double-blind, placebo-controlled study recruiting 130 healthy volunteers in the Netherlands. Participants must be 18 years or older.